Literature DB >> 15772819

Monitoring treatment response by the hepatitis C virus core antigen assay.

M Lindh1, M Lagging, J Westin, R Wejstål, G Norkrans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772819     DOI： 10.1007/s10096-005-1303-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  10 in total

1.  Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time.

Authors:  L Martin Lagging; Clementina E Garcia; Johan Westin; Rune Wejstål; Gunnar Norkrans; Amar P Dhillon; Magnus Lindh
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection.

Authors:  K Aoyagi; K Iida; C Ohue; Y Matsunaga; E Tanaka; K Kiyosawa; S Yagi
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

3.  Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.

Authors:  E Tanaka; C Ohue; K Aoyagi; K Yamaguchi; S Yagi; K Kiyosawa; H J Alter
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

4.  Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

Authors:  K Aoyagi; C Ohue; K Iida; T Kimura; E Tanaka; K Kiyosawa; S Yagi
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

5.  Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations.

Authors:  S R Lee; J Peterson; P Niven; C Bahl; E Page; R DeLeys; D Giordano-Schmidt; D Baggett; G Green
Journal:  Vox Sang       Date:  2001-01       Impact factor: 2.144

6.  Clinical application of hepatitis C virus core protein in early diagnosis of acute hepatitis C.

Authors:  M Kobayashi; E Tanaka; A Matsumoto; K Yoshizawa; H Imai; T Sodeyama; K Kiyosawa
Journal:  J Gastroenterol       Date:  1998-08       Impact factor: 7.527

7.  Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.

Authors:  Pascal Veillon; Christopher Payan; Gastón Picchio; Michèle Maniez-Montreuil; Philippe Guntz; Françoise Lunel
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.

Authors:  Françoise Lunel; Pascal Veillon; Isabelle Fouchard-Hubert; Véronique Loustaud-Ratti; Armand Abergel; Christine Silvain; Hervé Rifflet; Alain Blanchi; Xavier Causse; Yannick Bacq; Christopher Payan
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

9.  Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Authors:  Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay.

Authors:  Chiara Rebucci; Antonella Cerino; Agostino Cividini; Letizia Timo; Milena Furione; Mario U Mondelli
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.